Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials

V. V. Shah, T. C. Wikramanayake, G. M. DelCanto, C. van den Hurk, S. Wu, M. E. Lacouture, J. J. Jimenez

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Chemotherapy-induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65% of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited. To date, no clear guidelines have been established for optimum scalp cooling use as a treatment modality and its efficacy remain unknown. Nonetheless, scalp cooling remains the most widely utilized method for the prevention of CIA, and in December 2015, the United States Food and Drug Administration (FDA) cleared the DigniCap® Scalp Cooling System (Dignitana AB, Sweden) for marketing and the Orbis from Paxman® Coolers Ltd. received clearance in 2017. This literature review is one of the first to provide up-to-date review and side-by-side comparisons of controlled and randomized clinical trials (CCTs and RCTs) evaluating scalp hypothermia for the prevention of CIA. Our analyses of CCTs and RCTs to date show that scalp hypothermia is effective in reducing the occurrence rate of CIA, by 2.7-fold in the CCTs and 3.9-fold in the RCTs. These results suggest that scalp hypothermia represents an effective preventative measure for CIA, and provide guidance for management of anticipated alopecia following chemotherapy and for future investigations.

Original languageEnglish (US)
Pages (from-to)720-734
Number of pages15
JournalJournal of the European Academy of Dermatology and Venereology
Volume32
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Alopecia
Controlled Clinical Trials
Hypothermia
Scalp
Drug Therapy
Randomized Controlled Trials
United States Food and Drug Administration
Marketing
Sweden
Sample Size
Guidelines

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia : a review of controlled clinical trials. / Shah, V. V.; Wikramanayake, T. C.; DelCanto, G. M.; van den Hurk, C.; Wu, S.; Lacouture, M. E.; Jimenez, J. J.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 32, No. 5, 01.05.2018, p. 720-734.

Research output: Contribution to journalReview article

@article{b8a4313dd60841229ae7b7612fe0d2d4,
title = "Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials",
abstract = "Chemotherapy-induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65{\%} of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited. To date, no clear guidelines have been established for optimum scalp cooling use as a treatment modality and its efficacy remain unknown. Nonetheless, scalp cooling remains the most widely utilized method for the prevention of CIA, and in December 2015, the United States Food and Drug Administration (FDA) cleared the DigniCap{\circledR} Scalp Cooling System (Dignitana AB, Sweden) for marketing and the Orbis from Paxman{\circledR} Coolers Ltd. received clearance in 2017. This literature review is one of the first to provide up-to-date review and side-by-side comparisons of controlled and randomized clinical trials (CCTs and RCTs) evaluating scalp hypothermia for the prevention of CIA. Our analyses of CCTs and RCTs to date show that scalp hypothermia is effective in reducing the occurrence rate of CIA, by 2.7-fold in the CCTs and 3.9-fold in the RCTs. These results suggest that scalp hypothermia represents an effective preventative measure for CIA, and provide guidance for management of anticipated alopecia following chemotherapy and for future investigations.",
author = "Shah, {V. V.} and Wikramanayake, {T. C.} and DelCanto, {G. M.} and {van den Hurk}, C. and S. Wu and Lacouture, {M. E.} and Jimenez, {J. J.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/jdv.14612",
language = "English (US)",
volume = "32",
pages = "720--734",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia

T2 - a review of controlled clinical trials

AU - Shah, V. V.

AU - Wikramanayake, T. C.

AU - DelCanto, G. M.

AU - van den Hurk, C.

AU - Wu, S.

AU - Lacouture, M. E.

AU - Jimenez, J. J.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Chemotherapy-induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65% of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited. To date, no clear guidelines have been established for optimum scalp cooling use as a treatment modality and its efficacy remain unknown. Nonetheless, scalp cooling remains the most widely utilized method for the prevention of CIA, and in December 2015, the United States Food and Drug Administration (FDA) cleared the DigniCap® Scalp Cooling System (Dignitana AB, Sweden) for marketing and the Orbis from Paxman® Coolers Ltd. received clearance in 2017. This literature review is one of the first to provide up-to-date review and side-by-side comparisons of controlled and randomized clinical trials (CCTs and RCTs) evaluating scalp hypothermia for the prevention of CIA. Our analyses of CCTs and RCTs to date show that scalp hypothermia is effective in reducing the occurrence rate of CIA, by 2.7-fold in the CCTs and 3.9-fold in the RCTs. These results suggest that scalp hypothermia represents an effective preventative measure for CIA, and provide guidance for management of anticipated alopecia following chemotherapy and for future investigations.

AB - Chemotherapy-induced alopecia (CIA) is a temporary, yet psychologically devastating form of hair loss that affects 65% of patients receiving cancer chemotherapy. In the 1970s, scalp hypothermia was introduced as a preventative measure against the development of CIA. Numerous studies provide evidence for the effectiveness of scalp cooling to prevent CIA, although results varied because of differences in chemotherapy regimen, cooling technique, mode of administration and patient factors. However, many of the existing studies are uncontrolled or consist of small sample sizes, and data from randomized, randomized studies are limited. To date, no clear guidelines have been established for optimum scalp cooling use as a treatment modality and its efficacy remain unknown. Nonetheless, scalp cooling remains the most widely utilized method for the prevention of CIA, and in December 2015, the United States Food and Drug Administration (FDA) cleared the DigniCap® Scalp Cooling System (Dignitana AB, Sweden) for marketing and the Orbis from Paxman® Coolers Ltd. received clearance in 2017. This literature review is one of the first to provide up-to-date review and side-by-side comparisons of controlled and randomized clinical trials (CCTs and RCTs) evaluating scalp hypothermia for the prevention of CIA. Our analyses of CCTs and RCTs to date show that scalp hypothermia is effective in reducing the occurrence rate of CIA, by 2.7-fold in the CCTs and 3.9-fold in the RCTs. These results suggest that scalp hypothermia represents an effective preventative measure for CIA, and provide guidance for management of anticipated alopecia following chemotherapy and for future investigations.

UR - http://www.scopus.com/inward/record.url?scp=85043691115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043691115&partnerID=8YFLogxK

U2 - 10.1111/jdv.14612

DO - 10.1111/jdv.14612

M3 - Review article

C2 - 28976026

AN - SCOPUS:85043691115

VL - 32

SP - 720

EP - 734

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 5

ER -